UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No.)*

KRYSTAL BIOTECH, INC.

(Name of Issuer)

Common Stock, par value \$0.00001 per share (Title of Class of Securities)

> 501147 102 (CUSIP Number)

December 31, 2017 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

□ Rule 13d-1(b)

 \Box Rule 13d-1(c)

⊠ Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 501147 102

(1)	(1) Names of reporting persons				
	Krish S	5. K	rishnan		
(2)					
	(a) 🗆	(b			
(3)	3) SEC use only				
(4)	(4) Citizenship or place of organization				
		r			
	U.S.A.				
		(5)	Sole voting power		
Nu	nber of		1,935,249		
shares		(6)	Shared voting power		
beneficially			112,162 (1)		
owned by each		(7)	Sole dispositive power		
reporting		(7)			
person			1,935,249		
with:		(8)	Shared dispositive power		
			112,162 (1)		
(9)					
(10)	2,047,4		aggregate amount in Row (9) excludes certain shares (see instructions)		
(10)	CHECK I	i uie	aggregate amount in Row (9) excludes certain shares (see instructions)		
(11)	Percent	of cla	ass represented by amount in Row (9)		
	19.9%	(2)			
(12)					
()	5100	-F 0.			
	IN				

(1) Reflects 112,162 shares of Common Stock held by the Krishnan Family Trust. Mr. Krishnan and his spouse are each joint beneficial owners of the Krishnan Family Trust with joint voting and investment control.

(2) The percentage calculation is based on 10,307,247 shares of Common Stock outstanding as of February 28, 2018, as reported in the Issuer's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 12, 2018.

CUSIP No.	501147 102		
Item 1(a).	Name of Issuer:		
	Krystal Biotech, Inc.		
Item 1(b).	Address of Issuer's Principal Executive Offices:		
	2100 Wharton Street, Suite 701		
	Pittsburgh, Pennsylvania 15203		
Item 2(a).	Name of Person Filing		
	Krish S. Krishnan		
Item 2(b).	Address of Principal Business Office or, if None, Residence		
	c/o Krystal Biotech, Inc.		
	2100 Wharton Street, Suite 701		
	Pittsburgh, Pennsylvania 15203		
Item 2(c).	Citizenship		
	U.S.A.		
Item 2(d).	Title of Class of Securities:		
	Common Stock, par value \$0.00001 per share ("Common Stock")		
Item 2(e).	CUSIP Number:		
	501147 102		
Item 3.	If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:		
	Not Applicable		
	(a) \Box Broker or dealer registered under Section 15 of the Exchange Act.		
	(b) \Box Bank as defined in Section 3(a)(6) of the Exchange Act.		
	(c) \Box Insurance company as defined in Section 3(a)(19) of the Exchange Act.		
	(d) 🗆 Investment company registered under Section 8 of the Investment Company Act.		
	(e) \Box An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).		
	(f) \Box An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).		
	(g) \Box A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).		
	501147 102 If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: Not Applicable (a) Broker or dealer registered under Section 15 of the Exchange Act. (b) Bank as defined in Section 3(a)(6) of the Exchange Act. (c) Insurance company as defined in Section 3(a)(19) of the Exchange Act. (d) Investment company registered under Section 8 of the Investment Company Act. (e) An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E). (f) An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).		

- (h) \Box A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
- (i) 🛛 A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.

CUSIP No. 501147 102

- (j) \Box Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
- (k) Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

Item 4.	Ownership
	(a) Amount beneficially owned:
	See the response to Item 9 on the attached cover page.
	(b) Percent of class:
	See the response to Item 11 on the attached cover page.
	(c) Number of shares as to which such person has:
	(i) Sole power to vote or to direct the vote:
	See the response to Item 5 on the attached cover page.
	(ii) Shared power to vote or to direct the vote:
	See the response to Item 6 on the attached cover page.
	(iii) Sole power to dispose or to direct the disposition of:
	See the response to Item 7 on the attached cover page.
	(iv) Shared power to dispose or to direct the disposition of:
	See the response to Item 8 on the attached cover page.
Item 5.	Ownership of Five Percent or Less of a Class.
	Not applicable.
Item 6.	Ownership of More than Five Percent on Behalf of Another Person.
	Not applicable.
Item 7.	Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not applicable.
Item 8.	Identification and Classification of Members of the Group.
	Not applicable.
Item 9.	Notice of Dissolution of Group.
	Not applicable.
Item 10.	Certifications.
	Not applicable.

SIGNATURE

After reasonable inquiry and to the best of his knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: April 4, 2018

/s/ Krish S. Krishnan Krish S. Krishnan